"Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102" Read the press release from January 5, 2023 here: Read the press release from January 9, 2023 here: Received Investigational New Drug (IND) clearance from the FDA to conduct a clinical Phase 2 trial for its lead asset, AZ-3102, for the treatment of GM2 and Niemann-Pick disease type C (NP-C). Azafaros’s RAINBOW Phase 2 trial is a multinational, double-blind, placebo-controlled, parallel-g